CPHI Online is the largest global marketplace in the pharma ingredients industry
Rx-360 Summary of ICH Q3D Draft
ICH posted the 79-page, step 2b version of ICHQ3D, Guideline for Elemental Impurities on its website on 5 August 2013.
Consultation comments are due to both FDA and EMA in December 2013. The scope of the guideline includes chemically synthesised drugs, proteins and polypeptides made using cell culture expression systems and resulting conjugated proteins/polypeptides. Elemental impurities in drug product may come from a variety of sources including those added during chemical synthesis, the presence of elemental impurities in raw materials, or those that result from contact with processing equipment.
This guideline identifies elemental impurities that may have potential health/toxicology impact, establishes Permitted Daily Exposure (PDE) of those impurities and addresses controls necessary to maintain the impurities below the recommended PDE. The document includes seven sections (not including the Introduction and Scope) and four appendices as follows:
• Safety Assessment of Potential Elemental Impurities (pages 2-4)
• Element Classification (page 4)
• Assessment and Control of Elemental impurities (pages 5-13)
• Speciation (page 14)
• Analytical Procedures (page 14)
• Life-Cycle Management of the Control Strategy for Elemental Impurities
• Recommendations for Submission of Elemental Impurities Control Strategy (page 14)
• Appendix 1: Method for Establishing Exposure Limits (pages 20–22)
• Appendix 2: Established PDEs for Elemental Impurities (pages 23–25)
• Appendix 3: Individual Safety Assessments (pages 25–69)
• Appendix 4: Illustrative Example — Calculation Options for Converting PDEs to Concentrations (pages 69–79).
To view or download the ICH Q3D Document, click here
To view or download the Rx-360 Summary, click here
This second facility gives the company a significant power multiplier for export capacity and geographical reach
News CPHI Discover: Remote excipient audits are on the increase, but we must do more to develop novel excipientsAhead of the session, Value Added Excipients to Unlock the Potential of APIs, at CPHI Discover on Thursday 18th May – global pharma’s largest ever virtual gathering – we spoke with one of the speakers, Dr Iain Moor...
Need clarity on determining your QA from your QbD and your cGMPs? You’re not alone! In our new Pharma Explained series from CPHI, we bring you clear cut definitions from industry experts on a myriad of Pharma Terms, delivered in bitesize video presenta...
News Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situationsDr Scott Gottlieb shares insights into COVID-19 vaccine development, the upcoming US election and pharma pricing at the CPHI Festival of Pharma
Inspection conducted remotely using video-conferencing and an online private document sharing platform.
Decision clears legal pathway to expand access for patients living with multiple sclerosis in markets across Europe.
The pandemic that has swept over the world in 2020 has caused huge disruption to the European pharmaceutical industry's regulatory procedures and supply chain management. But the crisis has also provided a platform for a learning process for the sy...
The European Medicines Agency's human medicines committee (CHMP) has recommended the suspension of European marketing authorizations of generic medicines tested by Panexcell Clinical Laboratories at its site in Mumbai, India, citing irregularities in h...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
Generate high-quality, engaged leads for your business, all year round
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
Your company’s profile boosted at all participating CPHI events
An easy-to-use platform with a detailed dashboard showing your leads and performance